Contemporary role of cardiac magnetic resonance in the management of patients with suspected or known coronary artery disease by Bazoukis, George et al.
medicina
Review
Contemporary Role of Cardiac Magnetic Resonance in the
Management of Patients with Suspected or Known Coronary
Artery Disease
George Bazoukis 1,*, Stamatis S. Papadatos 2, Archontoula Michelongona 3, Konstantinos Lampropoulos 4,5,
Dimitrios Farmakis 6 and Vassilis Vassiliou 7


Citation: Bazoukis, G.; Papadatos,
S.S.; Michelongona, A.;
Lampropoulos, K.; Farmakis, D.;
Vassiliou, V. Contemporary Role of
Cardiac Magnetic Resonance in the
Management of Patients with
Suspected or Known Coronary Artery





Received: 5 April 2021
Accepted: 21 June 2021
Published: 24 June 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Cardiology, Larnaca General Hospital, 6051 Larnaca, Cyprus
2 Department of Anatomy, Histology and Embryology, School of Health Sciences, University of Ioannina,
451 10 Ioannina, Greece; stamspap@gmail.com
3 Cardiology Department, “Tzaneio” General Hospital of Piraeus, 185 36 Piraeus, Greece;
pas.mixelogona@hotmail.com
4 Department of Cardiology, General Hospital of Athens “Evangelismos”, 106 76 Athens, Greece;
konlampropoulos@yahoo.gr
5 Department of Pathophysiology, School of Medicine, European University of Cyprus, 1678 Nicosia, Cyprus
6 Shakolas Educational Center for Clinical Medicine, University of Cyprus Medical School, Palaios Dromos
Lefkosias Lemesou No.215/6, Aglantzia, 2029 Nicosia, Cyprus; farmakis.dimitrios@ucy.ac.cy
7 Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich NR4 7UQ, UK;
v.vassiliou@uea.ac.uk
* Correspondence: gbazoykis@med.uoa.gr; Tel.: +30-6983241394
Abstract: Cardiac magnetic resonance imaging (CMR) is a useful non-invasive radiation-free imaging
modality for the management of patients with coronary artery disease (CAD). CMR cine imaging
provides the “gold standard” assessment of ventricular function, late gadolinium enhancement
(LGE) provides useful data for the diagnosis and extent of myocardial scar and viability, while stress
imaging is an established technique for the detection of myocardial perfusion defects indicating
ischemia. Beyond its role in the diagnosis of CAD, CMR allows accurate risk stratification of patients
with established CAD. This review aims to summarize the data regarding the role of CMR in the
contemporary management of patients with suspected or known coronary artery disease.
Keywords: cardiac magnetic resonance; coronary artery disease; chronic coronary syndromes; late
gadolinium enhancement; stress cardiac magnetic resonance imaging; diagnosis; prognosis
1. Introduction
Despite the variability in the prevalence of chronic coronary syndromes in various re-
gions, the disease remains one of the main causes of death worldwide [1]. Invasive coronary
angiography is the gold standard in assessing the presence and severity of coronary artery
stenoses. However, the invasive nature and potential complications associated with this, as
well as the radiation exposure, minimize its role as a first-line screening or diagnostic tool in
assessing patients with suspected or known coronary artery disease (CAD). Furthermore,
recent data have shown the limited value of concomitant revascularization offered by
coronary angiography in chronic coronary syndromes [2]. Computed tomography (CT)
angiography is a non-invasive tool for the exclusion of significant coronary stenosis in
low-risk patients, but radiation exposure and inadequate imaging in specific populations
(irregular rhythm, tachycardia, obesity, calcified coronary arteries) raises major concerns
for its widespread use [3]. On the other hand, cardiac magnetic resonance (CMR) imaging
is a radiation-free and accurate imaging modality. Among the different CMR modalities,
cine cardiac imaging is useful for the assessment of global and regional ventricular function
for both the left and the right ventricle, late gadolinium enhancement (LGE) provides
useful data for the identification of myocardial scar, the estimation of myocardial infarction
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size and the assessment of myocardial viability, while stress CMR is an established tech-
nique for the detection of perfusion defects indicating myocardial ischemia (Figure 1) [4].
Furthermore, it is well-established that stress CMR can be a cost-effective tool prior to
coronary angiography in patients at risk of obstructive CAD [5]. In addition, in patients
with suspected CAD, CMR-guided care was found to be superior to National Institute
for Health and Care Excellence (NICE) guideline-directed care in reducing unnecessary
angiography within 12 months while no significant difference was found compared to
myocardial perfusion scintigraphy (MPS)-guided care [6]. According to current guidelines,
CMR can also be used for the risk stratification of chronic coronary syndrome patients.
More specifically, patients with ≥2 of 16 segments with stress perfusion defects or ≥3
dobutamine-induced dysfunctional segments are classified as having a high event risk and
according to the guideline writing committee are likely to benefit from revascularization [3].
This review aims at summarizing the role of CMR in the contemporary management of
patients with suspected or known CAD.
Figure 1. Role of cardiac magnetic resonance in the management of patients with suspected or known coronary artery
disease. T2* can be considered an observed T2, whereas the T2 can be considered the natural T2 of the tissue being imaged.
2. The Role of CMR in the Detection of Significant CAD
The role of CMR as an accurate tool for the evaluation of ventricular dimensions and
function has been demonstrated since the 1990s [7–9]. High-quality images achieved by
CMR can be used for the evaluation of global and regional wall motion abnormalities.
CMR imaging is considered as the gold-standard tool for the accurate estimation of left
ventricular ejection fraction (LVEF).
In the early 1990s, experimental studies confirmed the role of the gadolinium-enhanced
CMR imaging in the identification of infarcted myocardium after coronary occlusion [10].
LGE location can indicate both the presence and extent of myocardial infarct. Furthermore,
it is well-established that contrast-enhanced MRI can be used to identify myocardial
viability in patients with CAD prior to revascularization procedure [11]. Specifically, it has
been found that the percentage of the LV that is both dysfunctional and not hyperenhanced
before revascularization is strongly related to the degree of improvement in LVEF following
revascularization [11]. However, it should be noted that the absence of LGE rules out
myocardial damage relating to previous myocardial infarction (e.g., if a vessel was not
fully occluded as seen in NSTEMI, there might be no myocardial scar in that corresponding
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territory), but cannot be used for ruling out significant CAD, as ischemia itself is not
identified using the LGE method.
In this context, perfusion CMR can be used to identify patients with significant, and
functional, CAD. A case report published in 1990 highlighted the role of CMR with dipyri-
damole infusion for the detection of CAD in patients with suspected CAD [12]. Nowadays,
perfusion CMR is mainly performed using vasodilators (adenosine or regadenoson) to
assess perfusion abnormalities [13,14] or using dobutamine to evaluate regional wall mo-
tion abnormalities [15]. Perfusion CMR can discriminate patients with functional coronary
stenosis, but if normal, cannot be used to rule out CAD completely as mild non-significant
stenosis will still give a normal test. A large prospective real-world study (CE-MARC
study) established the superiority of multiparametric CMR consisting of cine imaging, LGE,
rest and adenosine stress perfusion, over SPECT as well as its high diagnostic accuracy in
CAD [16]. Another multicenter prospective study showed that fewer patients underwent
index revascularization in the perfusion CMR-guided group compared to the fractional
flow reserve (FFR)-guided group, while perfusion CMR was non-inferior to FFR for the
prediction of major adverse cardiac events [17]. A recent Australian study showed that after
a positive or inconclusive electrocardiographic stress test in patients with chest pain, stress
CMR was the most cost-effective approach for diagnosing significant CAD in Australia’s
healthcare system, prior to considering invasive angiography when CMR was positive
or inconclusive [18]. A recent meta-analysis concluded stress CMR had a specificity of
91% for ruling out significant CAD with 81% sensitivity [19], whilst the same authors
identified coronary CT angiography as sensitive (88%) to detect functionally significant
coronary stenosis. Even with the introduction of quantitative myocardial perfusion with
CT angiography, the balance is still in favor of CMR; a recent study confirmed that both
visual and quantified CMR perfusion outperformed visual CT angiography with perfusion
for the diagnosis of hemodynamically significant CAD [20]. Advancements in CMR have
also allowed in selected patients to combine coronary anatomy imaging (especially of
proximal coronaries) and perfusion CMR to improve detection accuracy of any significant
coronary stenosis [21–23].
One recent study showed that multiparametric exercise stress CMR accurately corre-
lated with FFR coronary angiography, indicating feasibility [23]. A recent study by Zhang
et al. showed that the 3-Tesla (T) CMR coronary angiography improved the sensitivity
and diagnostic accuracy for CAD detection compared to myocardial perfusion imaging
and LGE alone [24]. Another study which included symptomatic postmenopausal women
proposed a combination of two negative stress imaging results (stress CMR with stress
echocardiography or single positron emission tomography (SPECT)) for detection of CAD
and for risk stratification purposes as this strategy yielded higher accuracy [25]. With
regards to perfusion CMR, high-resolution (1.6 × 1.6 mm in-plane) perfusion-CMR has
been found to be more accurate as far as the detection of CAD in both single- and multi-
vessel disease is concerned, compared to the standard-resolution (2.5 × 2.5 mm in-plane)
acquisition [26]. Another recent study compared 1.5T to 3T CMR and revealed that 3T
CMR had similar diagnostic performance in detecting significant CAD. However, 3T CMR
had a greater performance in patients with multi-vessel CAD without old MI compared to
1.5T CMR [27].
CMR is additionally used for the diagnosis of CAD in specific populations. CMR
imaging constitutes an important diagnostic tool in patients with heart failure. Specifically,
a recent cohort study showed that in patients with unexplained reduced LVEF, performing
coronary angiography only in patients with a presence of myocardial ischemic scar may
significantly decrease the number of unnecessary coronary angiographies [28]. Moreover,
in patients with decreased LVEF but without LGE, a perfusion CMR or anatomical delin-
eation of coronary arteries is needed. In patients with chronic LV dysfunction due to CAD,
delayed enhancement CMR was found to provide the highest sensitivity and negative
predicting value for predicting improved segmental LV contractile function after revascu-
larization, whereas low dose dobutamine CMR provides the best specificity and positive
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predicting value [29]. Stress CMR has been studied for the detection of silent ischemia in
patients with antiphospholipid syndrome [30]. In another study which enrolled children
with Kawasaki disease and CAD, stress CMR was found to have 100% positive agreement
and >90% negative and overall agreement with moderate to severe coronary artery stenoses
as depicted by coronary artery angiography [31]. Although further investigation is needed,
stress perfusion CMR could possibly be used as an alternative to the coronary angiography
follow-up method in patients with left main stenting [32]. The implementation of CMR
in evaluating these high-risk patients has the advantage of avoiding radiation and com-
plications related to invasive procedures. However, multicenter prospective studies are
needed to validate the utility of CMR in follow-up of patients undergoing PCI of the left
main coronary artery. Finally, CMR may play a role in identifying the subgroup of patients
with chronic total occlusions (CTO) that may benefit from revascularization [33]. In this
setting, the CARISMA-CTO study showed that the implementation of a multi-parameter
CMR protocol to study viability/ischemia can help to identify the best candidates for
CTO-PCI [34]. This is of great importance considering the high percentage of complications
related to complex PCI procedures.
Contrast-enhanced CMR can also be used for the identification of microvascular
dysfunction following reperfusion while microvascular obstruction was found to predict
major adverse cardiovascular events and cardiac death [35]. In women with ischemia
and non-obstructive CAD, CMR-derived circumferential strain has been found to predict
coronary microvascular dysfunction [36]. Furthermore, patients with typical angina and
risk factors for microvascular disease were found to have reduced stress myocardial
perfusion and myocardial perfusion reserve compared to healthy controls [37] and this
perfusion defect is in a characteristic global pattern. Therefore, in the last 30 years, the
update of CMR has increased significantly. Newer developments have enabled accurate
visualization of the important proximal and mid parts of the coronaries and quantified
perfusion provides incremental value in addition to the established anatomical, volumetric
analysis and LGE for scar identification and viability.
CMR is a key diagnostic tool in the evaluation of patients presenting with myocardial
infarction with non-obstructed coronary arteries (MINOCA) because it not only provides
useful data about the potential causes but may also provide confirmation of the diagnosis
of AMI [38]. It has been found that CMR performed within seven days of presentation
can contribute to a diagnosis in nearly 90% of patients presenting with acute chest pain,
elevated serum troponin and non-obstructed coronary arteries [39]. Interestingly, the role
of CMR in this setting was confirmed by the results of a meta-analysis [40]. Specifically,
this study showed that CMR findings reasserted myocarditis as the leading diagnosis in
patients with MINOCA [40].
3. Role of CMR in the Risk Stratification of Patients with CAD
Myocardial fibrosis assessment can improve the prognostic role of CMR in patients
with CAD. Catalano et al. suggested that beyond clinical and echocardiographic assess-
ment, LGE could be used to assess myocardial viability and to further stratify the risk
of death in patients with stable CAD [41]. Stress CMR can be used for risk stratification
purposes as well. Moderate to severe perfusion defects in stress CMR has been found to
predict cardiovascular events [42,43]. In addition, characterization of healthy non-infarcted
myocardium by native T1 imaging can be potentially used as a predictor of outcome in
patients with CAD, beyond the traditional risk tools [44]. CMR-derived coronary flow
reserve is another independent predictor of major adverse cardiovascular events in patients
with known or suspected CAD [45]. Moreover, the predictive values of coronary flow
reserve (as assessed by CMR) and stress perfusion CMR for major adverse cardiovascular
events were comparable in patients with known CAD [46]. Adding aortic stiffness (as
expressed by pulse wave velocity) to stress CMR could improve prediction of mortality,
acute coronary syndrome, heart failure, need for coronary revascularization and stroke [47].
Furthermore, it has been suggested that the implementation of a score combining clinical
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(age, sex, diabetes mellitus and left ventricular ejection fraction) and stress CMR data
(ischemic burden defined as the number of segments with stress-induced perfusion defects)
could predict the risk of long-term all-cause mortality in patients with known or suspected
CAD [48]. Appreciating that adenosine can be contraindicated in some individuals, newer
pharmacological vasodilators like regadenoson stress CMR can also be used to predict
adverse events in patients with known or suspected CAD. Specifically, normal perfusion
can identify patients with low risk of coronary revascularization, non-fatal myocardial
infarction, and cardiovascular death [49]. On the other hand, dobutamine CMR (nowadays
used predominantly if there are contraindications for adenosine or renal failure prohibiting
the use of gadolinium) plays an important role in predicting cardiac death and nonfatal
myocardial infarction during long-term follow-up [50]. A South Asian study showed that
the implementation of CMR-derived factors such as infarct size and wall motion score
index with LVEF can improve the risk stratification of patients with CAD and can lead to
cost-effective therapeutic strategies [51].
In patients with ischemic symptoms but no significant CAD, stress perfusion CMR
was found to be an independent predictor of major adverse cardiovascular events [52].
Furthermore, the role of dobutamine CMR can also be utilized to assess the functional
significance of anomalous coronaries, although physiological exercise CMR if available
is the preferred modality. The safety and prognostic value of stress CMR regarding the
occurrence of major adverse cardiovascular events in heart failure with reduced ejection
fraction (HFrEF) have also been studied [53]. Even in the elderly, dipyridamole stress
perfusion CMR was characterized as a safe diagnostic tool that could additionally identify
patients with a lower event rate of future cardiovascular event or death [54]. A meta-
analysis showed that a negative stress CMR study was associated with very low risk
of cardiovascular death and myocardial infarction in patients with known or suspected
CAD [55]. Similarly, a meta-analysis performed by Gargiulo et al. showed that stress
CMR has a high negative predictive value for adverse cardiac events, and the absence of
inducible perfusion defect or wall motion abnormality shows a similar ability to identify
low-risk patients with known or suspected CAD [56].
A multi-center retrospective study concluded that a stress CMR without evidence of
ischemia or LGE identified patients at low risk of adverse cardiac events [57]. Similarly, a
meta-analysis showed that the presence and size of LGE in patients with CAD can predict
mortality and major adverse cardiovascular events [58]. It has been found that without
revascularization, the presence of dysfunctional viable myocardium as recognized by de-
layed enhanced CMR was an independent predictor of mortality in patients with ischemic
left ventricular dysfunction [59]. The number of scar segments as identified by LGE has
been found to be an independent predictor of cardiovascular events after CABG in patients
with a history of myocardial infarction [60]. Finally, CMR can also be used to identify
patients at risk of arrhythmias; it has been found that in CAD patients, scar extent studied
by LGE was significantly associated with appropriate implantable cardioverter defibrillator
(ICD) therapy and as a result, it can be used for identifying patients at high risk of future
lethal arrhythmic events [61–64]. Specifically, Alexandre J. et al. showed that in patients
with CAD and an ICD implanted either for primary or for secondary prevention of sudden
cardiac death (SCD), scar extent studied by LGE-CMR was significantly associated with
appropriate ICD therapies [61]. Similarly, another retrospective study showed that both
the percent of scar and number of transmural scar segments were significantly associated
with the occurrence of appropriate ICD therapies [62]. In the setting of ischemic cardiomy-
opathy with reduced ejection fraction, myocardial scar burden may predict gender-based
differences in survival benefit from ICDs [64].
Furthermore, quantification of the peri-infarct zone has also been found to predict
appropriate ICD therapy in ischemic cardiomyopathy [63]. These findings suggest the
use of LGE as a tool for the identification of CAD patients who are at high risk of fatal
arrhythmias. However, more studies are needed to confirm the role of LGE for improving
ICD treatment decisions.
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4. Limitations of CMR Imaging
Advantages and disadvantages of the commonly used imaging modalities in the
assessment of CAD patients are provided in Table 1. Limited access or availability and
the high cost are important barriers to CMR widespread use. Whilst CMR can provide
accurate answers to multiple cardiac questions, the magnetic nature means that it might
not be suitable, or might indeed be contraindicated, for some patients. Specifically, absolute
contraindications include: no MRI-compatible implantable electronic devices (although
still some centers are able to scan non-compatible devices following careful assessment and
modifications to the magnet sequences), metallic intraocular foreign bodies, implantable
neurostimulation systems, cochlear implants/ear implant, drug infusion pumps, catheters
with metallic components (Swan-Ganz catheter), metallic fragments such as bullets, cere-
bral artery aneurysm clips, magnetic dental implants, tissue expander, artificial limb, and
piercing [65]. Relative contraindications include: newly implanted coronary and periph-
eral artery stents, programmable shunts, airway stents or tracheostomy (except plastic),
intrauterine device, ocular prosthesis, surgical clips or wire sutures, joint replacement or
prosthesis, inferior vena cava filter, tattoos, colonoscopy procedure in the last eight weeks,
and claustrophobia [65]. In the case of gadolinium infusion, the following patients should
be carefully assessed or deferred: patients on dialysis, patients with a history of renal
disease or an estimated glomerular filtration rate below 30 mL/min/1.73 m2, patients
who had received a dose of contrast in the last 24 h, patients who had a previous allergic
or anaphylactic reaction to gadolinium, patients who have risk factors for nephrogenic
systemic fibrosis (NSF), patients with diabetes mellitus or hypertension who are receiving
treatment with medications, and patients who are pregnant [65].
Table 1. Advantages and disadvantages of the commonly used imaging modalities in the manage-





• No radiation exposure
• Low cost
• Poor ultrasound windows in
specific conditions (obesity,
COPD, etc.)
• Dependent on operator skills




• Large evidence base for
diagnostic accuracy and risk
stratification
• Radiation
• Suboptimal identification of
multi-vessel coronary disease
CMR





• No ionizing radiation
• High cost
• Acquisition time
• Use of contrast





• High negative predictive




• Difficulties mainly in
arrhythmias (tachycardia)
• Assessment limited in cases
with extensive coronary
calcification
SPECT, Single-Photon Emission Computed Tomography; CMR, Cardiac Magnetic Resonance; CCTA, Coronary
Computed Tomography Angiography.
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5. Recent Advances in CMR Imaging
Although the volumetric evaluation of LVEF is the cornerstone for assessing the car-
diac function, it is recognized that additional information, over and above ejection fraction,
can be beneficial. In this context, strain imaging can provide useful data for regional
abnormalities as well as to identify ventricular dysfunction in a pre-clinical stage [66,67].
However, normal values for the method and software cutoff need to be established. On the
other hand, quantitative myocardial perfusion is an accurate technique for the diagnosis of
occlusive CAD while it can also be used for ruling out significant CAD [68]. Artificial intel-
ligence has been implemented in perfusion CMR mapping [69] and provides instantaneous
quantification of myocardial perfusion by CMR. It has been found that in patients with
known or suspected CAD, quantitative myocardial blood flow measurement using artificial
intelligence is an independent predictor of adverse cardiovascular outcomes [69]. Coronary
imaging by CMR has also been improved in the last 10 years and it is likely that in the next
decade, the quality and speed by which this can be obtained will also be improve, making
it more clinically available. In the longer term, faster CMR protocols which will involve
less breath-holding will be facilitated, making a CMR study cheaper, quicker (and thus
available to further people) and more accurate than what it is currently [22].
6. Conclusions
CMR is an accurate and cost-effective imaging modality that could be used to identify
patients who will benefit from an invasive coronary angiography. Furthermore, it can
be used for risk stratification purposes in patients with known CAD. Recent advances
have increased the utility of CMR imaging in clinical practice in patients with suspected
or known CAD, and significant improvements on the horizon making CMR quicker and
cheaper signify that its role in clinical practice will only continue to expand.
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